Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Age-stratified cutpoints for aminoterminal pro-brain natriuretic peptide (NT-pro-BNP) concentrations are diagnostic in 83% of all subjects with acute dyspnea. This study analyzed subjects with NT-pro-BNP concentrations between the "rule-out" and "rule-in" cutpoints, the so-called natriuretic peptide gray zone. NT-pro-BNP concentrations, clinical characteristics, and 60-day mortality were studied in 1,256 acutely dyspneic patients from an international multicenter study. Of all subjects, 215 had gray-zone NT-pro-BNP concentrations, 116 of whom (54%) were diagnosed with heart failure (HF). Among these subjects, patients with HF were more likely to be older, to have a history of HF, to be in atrial fibrillation, and to have elevated troponin T concentrations compared with those without HF. In multivariate analysis, the use of loop diuretics on presentation (odds ratio [OR] 3.99, 95% confidence interval [CI] 1.58 to 10.1, p = 0.003), paroxysmal nocturnal dyspnea (OR 4.50, 95% CI 1.31 to 15.4, p = 0.02), jugular venous distention (OR 3.05, 95% CI = 1.06 to 8.79, p = 0.04), and the absence of cough (OR 0.18, 95% CI 0.06 to 0.52, p = 0.001) were associated with a diagnosis of acute HF in gray-zone patients. Subjects with HF and diagnostically elevated NT-pro-BNP concentrations had the highest mortality rates, subjects without HF and NT-pro-BNP concentrations < 300 ng/L had the lowest mortality rates, and subjects with gray-zone NT-pro-BNP had intermediate outcomes, irrespective of their final diagnoses. Adding specific clinical information to NT-pro-BNP improves diagnostic accuracy in subjects with intermediate NT-pro-BNP concentrations. Mortality rates in subjects with intermediate NT-pro-BNP concentrations are lower than in those with NT-pro-BNP concentrations diagnostic for HF but are higher than in subjects with NT-pro-BNP concentrations less than the gray zone.
Am J Cardiol 2006 Aug 01
PMID:Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. 1686 29

Periodically case studies emerge that demonstrate voluntary and forced coughing in ventricular fibrillation or asystole can maintain consciousness for up to 100 s. Forced cough is effective in producing co-ordinated abdominal muscle contraction and increases in intra-abdominal and thoracic pressures. These co-ordinated pressure changes are likely to be responsible for assisted circulation. In this short communication we discuss some of the possible abdominal physiological mechanisms for cough assisted circulatory support.
Int J Cardiol 2008 Jan 11
PMID:Co-ordinated intra-abdominal and intra-thoracic pressures regulate cough assisted cardiac circulatory support. 1732 15

The first description of severe pain in the distribution of the glossopharyngeal nerve is credited to Weisenberg, in 1910, in a patient with cerebellopontine angle tumor. However, it was Harris, in 1926, who coined the term glossopharyngeal neuralgia to describe this rare condition characterized by paroxysms of excruciating pain located laterally at the back of the tongue, soft palate, throat, and lateral and posterior pharynx, radiating to the ear. Swallowing, coughing, yawning or chewing may trigger pain, which usually lasts from seconds to minutes. The association between glossopharyngeal neuralgia and syncope is very rare, being identified by brief episodes of bradycardia, asystole, and hypotension. Such an association, with this same pathophysiology, was first described by Riley et al in 1942.
Arq Bras Cardiol 2006 Nov
PMID:Cardiac syncope induced by glossopharyngeal "neuralgia": a rare presentation. 1739 91

A rare case of fibrosing mediastinitis from histoplasmosis with extrinsic compression of the right pulmonary artery is reported. A 41-year-old patient presented with worsening symptoms of cough, fever, migratory arthralgia, chest pain, and progressive dyspnea. The pulmonary artery involvement was suspected by transthoracic echo and was confirmed by transesophageal echo, CT scan of chest, and right heart catheterization. Diagnosis of histoplasmosis was confirmed by biopsy and serological tests. Patient has been free from symptoms of pulmonary stenosis for 4 years after successful pulmonary artery stenting.
Int J Cardiol 2007 Jun 12
PMID:Fibrosing mediastinitis presenting as pulmonary stenosis: stenting works. 1739 16

Diverticulum of Kommerell is an outpouching from the descending aorta that, along with an aberrant subclavian artery and ductus arteriosus, may form a vascular ring compressing the trachea and/or the esophagus. It has been reported as an incidental finding as well as the cause of persistent dysphagia, cough, "asthma," or airway compromise at various ages but has never been reported as a cause of esophageal atresia in a newborn. We present a newborn with diverticulum of Kommerell, a vascular ring, and esophageal atresia.
Pediatr Cardiol
PMID:Esophageal atresia and diverticulum of Kommerell. 1753 Mar 18

A 50 years old male with previous history of dilated cardiomyopathy was admitted to cardio-intensive unit with dyspnea, cough, ascites and lower limb edema ascending to the inguinal region. 2D-Ecocardiogram revealed large pericardial effusion, without signs of diastolic restriction. The patient underwent pericardial drainage, which rapidly recollected in the following day. Abdominal ultrasound showed fibrotic and reduced size liver and subsequent radionuclide scan demonstrated direct communication between peritoneal and pericardial spaces. With the resolution of ascites, pericardial effusion did not recur. Embryologic explanation of this rare condition is still elusive, but incomplete closure of diaphragmatic muscle and thoracic-abdominal communication may represent the model of this anatomic functional anomaly.
Int J Cardiol 2008 Aug 01
PMID:Large pericardial effusion due to peritoneopericardial fistula. 1771 57

Hypertension is a common chronic disease that leads to significant cardiovascular morbidity and mortality worldwide. Blood pressure control is critical in reducing the end-organ complications, such as stroke, myocardial infarction, heart failure, or kidney disease. Currently available antihypertensive agents work by different mechanisms to reduce blood pressure. Aliskiren, a novel direct renin inhibitor, lowers blood pressure by decreasing renin activity, and angiotensin I and II levels. At the approved dosage (150-300 mg once daily), it reduces systolic blood pressure by 12-16 mm Hg and diastolic blood pressure by 2-12 mm Hg. In studies its efficacy was comparable to losartan 100 mg, irbesartan 150 mg, and valsartan 80-320 mg. When used adjunctively with ramipril, an angiotensin-converting enzyme (ACE) inhibitor, valsartan, an angiotensin II receptor blocker (ARB), or hydrochlorothiazide, a diuretic, it provides additional blood pressure reduction compared with placebo or monotherapy. Aliskiren is well tolerated, with the most common side effects being gastrointestinal symptoms, fatigue, weakness, and headache. In short-term clinical trials, aliskiren caused fewer disturbances in potassium levels when compared with hydrochlorothiazide, ACE inhibitors and ARBs. Long-term data on morbidity and mortality outcomes are not currently available, thus it is unknown whether aliskiren would join ACE inhibitors and ARBs as the preferred hypertensive agents for end organ protection. At this time, aliskiren should be considered as an alternative agent for mild-to-moderate hypertension, or as an adjunctive therapy when preferred agents fail to maintain optimal blood pressure control. It is also an option for those patients who have contraindications or intolerability to other antihypertensive agents, including dry cough induced by ACE inhibitors.
Cardiol Rev
PMID:Aliskiren: an oral renin inhibitor for the treatment of hypertension. 1809 68

In a 56-year-old woman with a secundum-type atrial septal defect, a closure device was successfully implanted with primarily adequate positioning of the occluder. Two weeks after discharge, the patient developed paroxysmal coughing that probably led to a device dislocation. Months later, a considerable left-to-right shunt was detected, and the device was found to be ingrown in a defective position and had to be removed surgically. In conclusion, the case demonstrates that recurrent coughing may interfere with closure devices and may lead to dangerous dislocation.
Am J Cardiol 2008 Feb 15
PMID:Device dislocation, probably due to paroxysmal coughing early after percutaneous closure of secundum type atrial septal defect. 1831 76

Cough is a common symptom in cardiovascular disorders and may be defined as an explosive expiration which helps in clearing the tracheobronchial system from secretions and foreign bodies. It is caused by a variety of cardiac and non-cardiac disorders. Although cough is generally accepted as an ominous symptom which indicates progressing or worsening disease state or drug side effect, it might sometimes be a life saving manoeuvre in the catheterization labs. The possible mechanisms by which cough helps us in the catheterization lab are discussed in this letter.
Int J Cardiol 2009 Apr 17
PMID:Cough: an ominous symptom and a life saving manoeuvre in cardiology. 1835 47

The incidence of enalapril-induced cough was evaluated in 199 patients with congestive heart failure. Cough was more frequent in class I or II patients (28%) than in class III (4.1%, p<0.01) and class IV (0%, p<0.01) patients. Brain natriuretic peptide level was lower in patients in the cough (+) group than in the cough (-) group (170+/-107 vs. 538+/-637 pg/ml, p<0.01). The incidence of enalapril-induced cough is low in patients with severe congestive heart failure and a cough can be a marker of non-severe heart failure.
Int J Cardiol 2009 Jun 26
PMID:Enalapril-induced cough is associated with non-severe heart failure. 1860 71


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>